Albrecht Kretzschmar

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Albrecht Kretzschmar, Dmitry Bichev et al. · European Journal of Cancer · 2011 · 615 citations

Medicine, Oncology, Pharmacotherapy +13

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry et al. · Annals of Oncology · 2009 · 534 citations

Medicine, Oncology, Pharmacotherapy +10

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

Rainer Porschen, Hendrik‐Tobias Arkenau, S. Kubicka et al. · Journal of Clinical Oncology · 2007 · 279 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning et al. · Annals of Oncology · 2005 · 222 citations · Full text

Medicine, Oncology, Pharmacology +10

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2023 · 195 citations

Medicine, Oncology, Perioperative Medicine +17